In contrast, tumors collected at the efficacy end point (tumor volume > 2000 mm3) revealed greater inhibition of p-ERK1/2 in tumors from combination-treated RKO xenografts compared to vehicle, GSK525762, or trametinib monotherapy (Supplemental Figure S16). Here, MAPK3 is linked to neoplasm.